Pulmatrix, Inc. PULM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-228.32
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$5.2M | — | — | $3.8M |
| 2024 | $7.8M | -$9.6M | — | -$11.1M | $8.9M |
| 2023 | $7.3M | -$14.1M | — | -$16.7M | $18.0M |
| 2022 | $6.1M | -$18.8M | — | -$19.4M | $31.1M |
| 2021 | $5.2M | -$20.2M | — | -$19.9M | $47.4M |
| 2020 | $12.6M | -$19.3M | — | -$12.8M | $23.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -228.32 (distress)
- Working capital / assets 0.918
- Retained earnings / assets -73.041
- EBIT / assets -1.249
- Equity / liabilities 11.581
Source: SEC EDGAR filings · CIK 0001574235 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.